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Abstract
Background: Ring chromosome 18 [r(18)] syndrome represents a relatively rare condition with a complex clinical
picture including multiple congenital dysmorphia and varying degrees of mental retardation. The condition is
cytogenetically characterized by a complete or mosaic form of ring chromosome 18, with ring formation being usually
accompanied by the partial loss of both chromosomal arms. Here we observed a 20-year-old male patient who along
with the features typical for r(18) carriers additionally manifested a severe congenital subaortic stenosis. To define the
genetic basis of such a compound phenotype, standard cytogenetic and high-resolution molecular-cytogenetic
analysis of the patient was performed.
Case presentation: Standard chromosome analysis of cultured lymphocytes confirmed 46, XY, r(18) karyotype. Array-
based comparative genomic hybridization (array-CGH) allowed to define precisely the breakpoints of 18p and 18q
terminal deletions, thus identifying the hemizygosity extent, and to reveal an additional duplication adjoining the
breakpoint of the 18p deletion. Apart from the terminal imbalances, we found an interstitial microdeletion of 442 kb in size
(18q12.1) that encompassed DTNA gene encoding α-dystrobrevin, a member of dystrophin-associated glycoprotein
complex. While limited data on the role of DTNA missense mutations in pathogenesis of human cardiac abnormalities exist,
a microdeletion corresponding to whole DTNA sequence and not involving other genes has not been earlier described.
Conclusions: A detailed molecular-cytogenetic characterization of the patient with multiple congenital abnormalities
enabled to unravel a combination of genetic defects, namely, a ring chromosome 18 with terminal imbalances and DTNA
whole-gene deletion. We suggest that such combination could contribute to the complex phenotype. The findings
obtained allow to extend the knowledge of the role of DTNA haploinsufficiency in congenital heart malformation, though
further comprehensive functional studies are required.
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Background
Ring chromosome 18 [r(18)] is a relatively rare structural
chromosomal abnormality characterized by the replace-
ment of a normal chromosome 18 by the ring chromo-
some. A ring formation is usually accompanied by the
partial loss of both chromosomal arms that in turn leads
to hemizygous state of genes from the deleted regions
[1–3]. Patients bearing a r(18) have complex clinical
presentation that combines phenotypic features of 18p
(OMIM #146390) and 18q (OMIM #601808) deletion
syndromes and includes multiple congenital defects with
varying degrees of mental retardation [4, 5]. The most
typical features include short stature, multiple facial
dysmorphia such as a carp-shaped mouth, cleft lip/pal-
ate, broad flat nose and epicanthic folds, hypertelorism,
hearing loss, different eye abnormalities, microcephaly,
abnormal white matter, hypotonia, and, rarer, congenital
heart defect most commonly in a form of pulmonary
stenosis [2–6].
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There is considerable phenotypic variability among
patients with ring 18 that is mainly due to differences in
extent of hemizygosity, ring chromosome instability and
somatic mosaicism [3, 4, 7, 8]. Besides, the presence of add-
itional chromosomal abnormalities also can be considered.
In this regard, whole-genome high-resolution cytogenetic
analysis proves to be indispensable for comprehensive diag-
nosis, accurate genetic counseling and clinical management
of the families.
In this report, we characterize a patient who apart
from r(18) clinical manifestations exhibited a severe con-
genital subaortic stenosis, a heart malformation usually
not described in ring 18 cases. Array-based comparative
genomic hybridization (aCGH) analysis allowed us to
refine the boundaries of r(18) terminal deletions and
thus to define a hemizygous region responsible for the
main phenotypic features. We also revealed an intersti-
tial heterozygous microdeletion encompassing a cardiac
gene, which might have an additional impact on the
heart malformation of the patient.
Case presentation
Clinical report
The proband was born at term as the first child of healthy
non-consanguineous parents of Russian origin. At birth
the patient presented multiple malformations typical for
r(18) syndrome, namely microcephaly, low-set deformed
ears, broad flat nose, a carp-shaped mouth, gothic palate,
hypertelorism, broad and short great toe and syndactyly.
At 3 years old, a subaortic stenosis and mental retardation
were diagnosed. Two years later, at 5 years, subaortic
stenosis was surgically corrected followed by a repeated
operation and Ross-Konno procedure at the age of 13 and
balloon angioplasty at the age of 18 years.
Results
The standard cytogenetic analysis showed the presence
of r(18) in proband’s karyotype (46, XY, r(18)) (Fig. 1,
Additional file 1) with the ring chromosome being
revealed in all analyzed metaphase plates. The deletion
of both 18p and 18q terminal regions of r(18) was un-
ambiguously confirmed by FISH with probes marking
subtelomeric regions of chromosome 18 (Fig. 2c, d).
That is, hybridization signals were specifically detected
on a normal chromosome 18 homolog but were not
revealed on r(18).
Array-CGH analysis showed that 18p terminal deletion
corresponded to the 18p11.32 cytoband (Fig. 2a) and
spanned 305 kb (chr18: 132096–437282 bp, hg18 build).
The 18q terminal deletion was assigned to the 18q22.3–
q23 chromosomal region (Fig. 2a) with length about
7.5 Mb (chr18: 68533620–76083117 bp, hg18 build) that
involves many annotated genes including OMIM morbid
genes TSHZ1 and CTDP1. Additionally, a duplication
adjoining the breakpoint of the 18p deletion and spanning
approximately 2 Mb (chr18: 467510–2480365 bp, hg18
build) was detected. Apart from the terminal imbalances,
an interstitial heterozygous deletion of 442 kb in size
(chr18: 30327060–30769230 bp, hg18 build) was found on
chromosome 18 (Fig. 2a, b). The deletion involved only
the DTNA gene (http://www.ncbi.nlm.nih.gov/gene, ID:
1837; OMIM 601239) and encompassed the whole gene
Fig. 1 Standard cytogenetic analysis of the patient. GTG-banded karyotype showing the presence of ring chromosome 18 (karyotype 46, XY, 18(r)).
Red arrow points to the ring chromosome (mar: marker)
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sequence. The deletion was verified by qPCR (Additional
file 2). As parental biomaterial was not available, we could
not determine the origin of the deletion.
Discussion
Here we report on one more case of ring chromosome
18. Whole-genomic microarray-CGH analysis allowed to
refine the r(18) deletion breakpoints with high resolution
and thus to define the content of hemizygous genes. The
18p deletion involved the very terminal chromosomal
region and affected the entire USP14 and THOC1 genes
and the most part of COLEC12 gene. These genes are
not assigned to morbid ones, and, according to currently
available data, they do not belong to critical regions and
have not been discussed as putative causative genes for
r(18) severe phenotypic features.
An additional relatively large duplication at the site of the
18p deletion breakpoint was revealed, which agrees with
the available data on high-resolution molecular-cytogenetic
analysis of patients with ring 18. That is, about 20 % of ring
Fig. 2 High-resolution molecular cytogenetic analysis of the patient. a, b Comparative genomic hybridization using Agilent 60 K microarray.
a The chromosome 18 view; oligonucleotides with log2 ratio ~ −1 (red dots, red rectangles) indicate deleted regions; oligonucleotides with log2
ratio ~ +0.6 (blue dots, blue rectangle) indicate a duplicated region. The boundaries of terminal deletions, a duplication and an interstitial deletion
(18q12.1) were defined with high resolution. b The enlarged 18q12.1 region with imported DGV and OMIM databases tracks and genes
annotations. The data illustrate the presence of DTNA deletion. c, d Fluorescent in situ hybridization (FISH) on metaphases from cultured
peripheral blood lymphocytes. FISH with probes to centromeric (aqua) and subtelomic (yellow) regions of chromosome 18 (ToTelVysion Probe Kit,
Abbott/Vysis; the probes to subtelomeric regions of chromosomes 11 and 12 (p – green, q – red) are added in the hybridization mix by the
manufacturer). Inserts show the enlarged view of the normal and the ring chromosome 18. The analysis confirmed the deletion of both terminal
regions on r(18)
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chromosome cases, including r(18), have been shown to be
accompanied by duplication of the regions bordering the
terminal deletion breakpoints [3, 9]. Together with hemi-
zygosity extent, ring chromosome instability and somatic
mosaicism, such duplications are regarded as a cause of
r(18) phenotypic heterogeneity. In the case presented here,
the duplication spanned about 2 Mb and involved eight
protein-coding genes, including OMIM genes COLEC12,
CETN1, TYMS, ENOSF1, YES1 and ADCYAP1. In DE-
CIPHER database, several CNV (copy number variant)
gains similar in position, length and gene content have been
described (Decipher IDs 289491, 252149, 253424) with
their pathogenicity and clinical significance being largely
uncertain. The phenotypes annotated for these cases have
included ataxia, oculomotor apraxia, and proportionate
short stature. The association between increased dosage of
the above-mentioned genes and congenital craniofacial
and/or cardiac defects has not been described. A patient
exhibiting ADCYAP1 (or, PACAP) overexpression, as a con-
sequence of a partial trisomy 18p, has suffered from severe
mental retardation [10]. This is a reasonable link, since
PACAP is known to encode a neuropeptide that plays a role
in regulation of neuronal development, differentiation and
survival [11–13]. Taking all of this into account, the re-
vealed 18p duplication does not seem to be responsible for
the severe congenital defects (facial dysmorphia and the
heart defect) presented by the patient but could contribute
to the individual phenotype, in particular, to mental delay.
The 18q terminal deleted region was quite extended and
encompassed 27 RefSeq protein coding genes including
several OMIM morbid genes known to be associated with
a number of particular congenital dysmorphia and intel-
lectual disability, which correlates with the patient’s
clinical manifestations. That is, heterozygous disruption of
TSHZ1 (teashirt zinc finger homeobox 1) gene was found
to be responsible for congenital aural atresia phenotype in
mice [14] and humans [15, 16]. Additionally, deletion of
this gene has been implicated in congenital foot malfor-
mations/deformations [15, 16] as well as in cleft lip and
palate formation [14, 16]. Finally, together with ZADH2
gene, TSHZ1 belongs to a critical region associated with
mood disorder in people with 18q distal deletion [17].
Mutations in CTDP1 gene were identified in Roma/Gypsy
population as a cause of Congenital Cataracts Facial Dys-
morphism Neuropathy (CCFDN) syndrome (OMIM
604168) characterized by anomalies of the eye, impaired
physical growth, mild facial dysmorphism and a hypo/de-
myelinating, symmetric, distal peripheral neuropathy [18].
The loss of SALL3, another gene located in the 18q-
deleted region, has been shown to underlie craniofacial
development in mice [19]. Some other genes from the
region are also known to be involved in regulation of
crucial biological functions, but their implications in r(18)
clinical features still need to be clarified.
On the whole, we conclude that the patient’s phenotypic
picture distinctive for ring chromosome 18 cases is largely
determined by haploinsufficiency as a consequence of
hemizygosity of the 18q22.3–q23 region. However, it is
worth noting that the patient also presented a severe con-
genital heart defect, namely, subaortic stenosis. At present,
there is a lack of data on genotype-phenotype correlations
for heart malformations in ring 18 individuals. Recently,
van Trier and coauthors reported on two patients with
18q terminal deletion and complex cardiac abnormalities
and compared the data with earlier published del(18q)
cases [20]. As a result, the authors have suggested the
most distal part of 18q as a critical overlapping region for
heart malformation.
According to the published data, the cardiac anomalies
that are predominantly described for r(18) and 18q deletion
syndrome include pulmonary stenosis and atrial septal
defects [3, 16, 20, 21]. Congenital subaortic stenosis is a
heart malformation not typical for ring chromosome 18
condition. The only example of association between hyper-
trophic subaortic stenosis and a ring chromosome from E
group, presumably r(18), was described by Wald and coau-
thors [22]. In that study, karyotyping was carried out on the
basis of chromosome morphology and tritiated tymedin in-
corporation pattern, and unambiguous identification of the
chromosome formed a ring was not possible. Besides, the
boundaries of ring chromosome terminal deletions, as well
as any additional subtle chromosomal rearrangements con-
tributing to the clinical picture could not be examined
without comprehensive cytogenetic and molecular-
cytogenetic analysis.
We showed that the patient was a carrier of an interstitial
deletion corresponded to whole DTNA gene. DTNA en-
codes α-dystrobrevin, a member of dystrophin-associated
glycoprotein (DAG) complex, which is thought to provide
the integrity and maintenance of sarcolemma and to be
involved in muscle contraction and relaxation signaling
[23–25]. The previous studies gave evidence that α-
dystrobrevin includes four main structural-functional
domains and directly interacts with some members of
DAG complex, in particular, with dystrophin, syntrophin
and sarcoglycan complex [23, 24, 26]. The current notion
of the DAG complex network in muscle and its schematic
illustration was provided by Nakamori and Takahashi [26].
It is now well known that abnormalities in different mem-
bers of this complex cause various muscular dystrophies
and cardiomyopathies. Specifically, mutations in the dys-
trophin gene are responsible for Duchenne (OMIM
#310200) and Backer (OMIM #300376) muscular dystro-
phies as well as for X-linked dilated cardiomyopathy
(OMIM #302045). Sequence variations in other DAG
members including α-, β-, γ-, and δ- sarcoglycans, integrin
α7 and laminin α2 are also found to underlie muscular
dystrophies and cardiomyopathies [27–32].
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Much less is known about α-dystrobrevin. According
to several studies, α-dystrobrevin deficiency is also asso-
ciated with congenital muscular dystrophy [26, 33–35].
At present, the data on α-dystrobrevin functioning in
heart and its role in pathogenesis of cardiovascular
diseases are especially limited. Mice deficient in α-
dystrobrevin exhibited both skeletal and cardiac myop-
athies [36]. Besides, the hearts of α-DB null (adbn−/−)
mice were shown to be highly susceptible to injury
during cardiac stress [25]. In human, it has been shown
that DTNA missense mutations were associated with left
ventricular noncompaction 1 cases (OMIM #604169) -
both isolated cases and/or conditions with associated
congenital heart defects including coronary artery anom-
alies, conotruncal anomalies, ventricular and atrial septal
defects, pulmonic stenosis, anomalous venous pulmon-
ary veins, hypoplastic left heart syndrome, Ebstein’s
anomaly [37–39].
With regard to DTNA, it proves to be especially import-
ant to focus on genotype/phenotype correlations not only
in cases of single nucleotide changes but whole-gene dele-
tion as well. There are five known α-dystrobrevin isoforms
resulting from alternative splicing [23, 40, 41], therefore in
case of complete gene deletion the depleted protein func-
tion can not be compensated by remaining isoforms. By
now, the condition of complete α-dystrobrevin gene dele-
tion has been modeled in mutant mice [42]. To our know-
ledge, just a few cases of 18q deletion involving DTNA
have been described in human. In particular, the data on
two deletions from PubMed literature [43, 44] and five
deletions from the DECIPHER database [45] are available
(Decipher IDs 250878, 260121, 276030, 286198, 288657).
Along with severe intellectual disability and motor delay,
in some of these cases the heart and great vessels’ malfor-
mation as well as hypotonia were observed. At the same
time, these deletions spanned as much as 3.2–14.5 Mb in
size, encompassed several morbid genes and, in some
cases, were associated with additional chromosomal
micro-rearrangements. For this reason, the interpretation
of genotype-phenotype correlation as well as the assess-
ment of DTNA deletion impact on the phenotypes is
ambiguous. Here, for the first time we presented a case of
the 18q12.1 deletion restricted only to DTNA gene in a
patient with subaortic stenosis that allows to suggest that
DTNA belongs to dosage sensitive genes and to extend
our knowledge of the role of DTNA haploinsufficiency in
congenital heart malformation.
Conclusions
In conclusion, we report on a patient with ring chromo-
some 18 phenotype combined with a congenital subaortic
stenosis. The results of array-CGH analysis imply that a
combination of several genetic aberrations such as terminal
imbalances of r(18) and 18q12.1 interstitial microdeletion
might contribute to the complex phenotype. Our study
draws attention to DTNA gene whose deficiency was
possibly implicated in the described congenital heart mal-
formation, but further careful functional studies are needed.
Here we support the utility of array-CGH analysis for ac-
curate individual diagnosis, disease prognosis and genetic
counseling of patients with multiple congenital defects and
non-typical clinical picture.
Methods
Routine analysis of G-banded metaphase chromosomes at
a resolution of 400 bands was performed using phytohaem-
agglutinin (PHA)-stimulated peripheral blood lymphocytes,
with fifteen metaphase plates being analyzed. Fluorescent
in situ hybridization (FISH) with molecular probes specific
to centromeric and subtelomeric regions of chromosome
18 (ToTelVysion Probe Kit, Abbott/Vysis) was carried out
on metaphase spreads of the same lymphocyte suspension.
Whole-genome DNA analysis was performed using oligo-
nucleotide array-based CGH. As a platform, Agilent 60 K
array with median probe spacing 41 kb was used (SurePrint
G3 Human CGH Microarray, Agilent Technologies, Santa
Clara, CA, USA). The study was performed according to
Helsinki Declaration and study approval was obtained from
Institutional Ethical Review Board at the Almazov Federal
Medical Research Centre in St. Petersburg. Written in-
formed consent was obtained from the patient and his
parents prior to investigation. Genomic DNA was extracted
from peripheral blood cells using a Puregene DNA Extrac-
tion Kit (Gentra, Qiagen, USA). The sample preparation
and the hybridization procedure were carried out according
to manufacturer’s recommendations. The data obtained
was processed and analyzed using CytoGenomics Software
(v3.0.1.1, Agilent Technologies) with imported tracks of
publically available databases of normal and pathogenic
human genome variants, such as Database of Genomic
Variants (DGV) [46] and Online Mendelian Inheritance in
Man database (OMIM) [47]. Additionally, the revealed
copy number variants were compared with the data from
DECIPHER [45] and pubmed [48] databases. CNVs (gains
and losses) were called using an aberration detection statis-
tical algorithm ADM-2, with a sensitivity threshold of 6.0.
All genomic coordinates refer to the human reference
assembly NCBI36 (hg18).
The loss of 18q12.1 region was confirmed by real-time
quantitative PCR (qPCR) using SYBR Green Master Mix
according to manufacturer’s recommendations (http://
www.evrogen.com/). The assay was performed for DTNA
gene sequence (exon 6; NG_009201.1) with the following
primers designed using NCBI Primer Blast tool [49]: F 5′-
TTGCGGGAAAATGCTCTGAAC-3′; R 5′- TAAGGAG
GAGGCTGATGGACT-3′. The quantity assessment of the
target sequence was carried out relative to a normal control
DNA. The relative copy number was evaluated using the
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comparative ΔΔCt method with the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) be-
ing used for normalization.
The structural variants were submitted to the DGV
archive [50] with accession number estd226.
Ethics, consent and permissions
Written informed consent was obtained from the patient
and his parent prior to investigation for publication of this
Case report and any accompanying images. A copy of the
written consent is available for review by the Editor-in-
Chief of this journal.
Additional files
Additional file 1: Standard cytogenetic analysis of the patient
(additional material). Two GTG-banded metaphase plates showing the
presence of ring chromosome 18 (karyotype 46, XY, 18(r)). Red arrows
point to a normal chromosome homolog 18 and to a ring chromosome
r(18). (PNG 437 kb)
Additional file 2: Confirmation of DTNA deletion in the patient
using quantitative real-time PCR analysis (qPCR). Description of data:
qPCR data revealed one copy of the DTNA gene (18q12.1) in a patient
DNA sample as compared to two copies of the gene in a normal control
DNA sample. The data was normalized against GAPDH gene using the
comparative ΔΔCt method. RQ (relative quantity) value is presented
along the vertical axis. Each reaction was reproduced (repeated) in
triplicate for both DNA samples (patient and control) and both genes
(DTNA and GAPDH). The series of four ten-fold dilutions were included
into analysis with the starting amount of DNA ~ 1 ng. The results
obtained for one of the dilutions are depicted in the figure; for the rest
dilutions, the ratio of quantity values between test and control samples
was the same. (PNG 8 kb)
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